Literature DB >> 34570943

Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.

Ryan Mooney1, Whitney Espinel1, Ashley Elrick1,2, Kelsey Kehoe1, Wendy Kohlmann1, Kimberly A Kaphingst1,2.   

Abstract

Women with a personal history of breast or ovarian cancer who previously had BRCA1/2 testing now have the opportunity for additional genetic risk information through multi-gene panel testing. However, little is known about women's receptivity to further contact and uptake of genetic counseling and updated genetic testing. Utilizing a clinic database to identify potential participants, we prospectively contacted women in the United States with a personal and/or family history of breast or ovarian cancer who had negative BRCA1/2 testing, which was performed primarily between 2011 and 2018. Eligible and interested participants were scheduled for a genetic counseling appointment to discuss updated genetic testing using a multi-gene panel. We attempted to contact 455 participants, screened 203 (45%), and 103 (23%) completed a pre-test genetic counseling visit to discuss updated testing. Of these, 88 participants had updated multi-gene panel testing. Participants had an average age of 59 years, and most (78%) had breast cancer with an average age of 45 at diagnosis. The majority (97%) of participants were white. Of participants who underwent panel testing, 13% (n = 11) had at least one pathogenic variant identified. Most participants (86%) had an out-of-pocket cost of $100 or less for their panel. There is a sizable population of women with a personal and/or family history of breast or ovarian cancer and negative BRCA1/2 test results who would qualify for updated multi-gene panel testing. In our study, 59% of those reached who were eligible completed a pre-test genetic counseling visit. Clinics could consider an outreach program to offer genetic counseling and updated genetic testing. Supports for this type of effort may include coordinators and genetic counseling assistants and an available database with patients' contact information and prior genetic test results. Updated testing allows women more information about their risk and may expand the value of genetic counseling.
© 2021 National Society of Genetic Counselors.

Entities:  

Keywords:  genetic counseling; genetic testing; genetics services; hereditary breast and ovarian cancer; multi-gene panel

Mesh:

Substances:

Year:  2021        PMID: 34570943      PMCID: PMC9206233          DOI: 10.1002/jgc4.1513

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.717


  20 in total

1.  Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.

Authors:  Lindsey Sawyer; Heather Creswick; Raymond Lewandowski; John Quillin
Journal:  J Genet Couns       Date:  2019-09-25       Impact factor: 2.537

2.  Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.

Authors:  Minerva A Romero Arenas; Thereasa A Rich; Samuel M Hyde; Naifa L Busaidy; Gilbert J Cote; Mimi I Hu; Robert F Gagel; Paul W Gidley; Camilo Jimenez; Michael E Kupferman; Susan K Peterson; Steven I Sherman; Anita Ying; Roland L Bassett; Steven G Waguespack; Nancy D Perrier; Elizabeth G Grubbs
Journal:  Ann Surg Oncol       Date:  2018-02-09       Impact factor: 5.344

3.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.

Authors:  Nicholas Hearle; Valérie Schumacher; Fred H Menko; Sylviane Olschwang; Lisa A Boardman; Johan J P Gille; Josbert J Keller; Anne Marie Westerman; Rodney J Scott; Wendy Lim; Jill D Trimbath; Francis M Giardiello; Stephen B Gruber; G Johan A Offerhaus; Felix W M de Rooij; J H Paul Wilson; Anika Hansmann; Gabriela Möslein; Brigitte Royer-Pokora; Tilman Vogel; Robin K S Phillips; Allan D Spigelman; Richard S Houlston
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

5.  Cancer Genetic Counseling and Testing in an Era of Rapid Change.

Authors:  Gillian W Hooker; Keelia Rhoads Clemens; John Quillin; Kristen J Vogel Postula; Pia Summerour; Rebecca Nagy; Adam H Buchanan
Journal:  J Genet Couns       Date:  2017-04-22       Impact factor: 2.537

6.  How we design feasibility studies.

Authors:  Deborah J Bowen; Matthew Kreuter; Bonnie Spring; Ludmila Cofta-Woerpel; Laura Linnan; Diane Weiner; Suzanne Bakken; Cecilia Patrick Kaplan; Linda Squiers; Cecilia Fabrizio; Maria Fernandez
Journal:  Am J Prev Med       Date:  2009-05       Impact factor: 5.043

7.  Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.

Authors:  Laurie E Steffen; Ruofei Du; Amanda Gammon; Jeanne S Mandelblatt; Wendy K Kohlmann; Ji-Hyun Lee; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Belinda Vicuña; Marc D Schwartz; Anita Y Kinney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-29       Impact factor: 4.254

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

9.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.

Authors:  Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

10.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.